Therefore, MOS, TPL2 and ERK1/2 inhibitors may be therapeutically useful for treating BCR::ABL1‐independent dasatinib‐resistant CML. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.